ClinicalTrials.Veeva

Menu
The trial is taking place at:
E

Epic Medical Research | Red Oak, TX

Veeva-enabled site

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Moderna logo

Moderna

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

Norovirus Acute Gastroenteritis

Treatments

Biological: mRNA-1403
Biological: Placebo
Biological: mRNA-1405

Study type

Interventional

Funder types

Industry

Identifiers

NCT05992935
mRNA-1403/1405-P101

Details and patient eligibility

About

The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of the Phase 2 Part of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants 18 to 80 years of age.

Enrollment

1,285 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Phase 1 Part: Adults 18 to 49 years of age at the time of consent or adults 60 to 80 years of age at the time of consent.
  • Phase 2 Part: Adults 18 to 80 years of age at the time of consent.
  • Body mass index of 18 to 39 kilogram/meter^2 (inclusive) at the Screening Visit.
  • Participants assigned female at birth are eligible to participate if they are not pregnant or breast/chest/body feeding.
  • A person of childbearing potential is using a highly effective contraceptive method.
  • Participant has provided written informed consent for participation in this study,

Key Exclusion Criteria:

  • Is acutely ill or febrile (temperature ≥38.0°C [100.4°F]) 72 hours prior to or at the Screening Visit or Day 1
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Has a medical, psychiatric, or occupational condition, including reported history of substance abuse, that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
  • Has a current or previous diagnosis of immunosuppressive condition, to include human immunodeficiency virus, or immune-mediated (autoimmune) disease that requires immunosuppressive therapies (drugs or biologics). The use of topical corticosteroids or other immunosuppressive agents (for example, topical calcineurin inhibitor) may be eligible for participation at the discretion of the Investigator.
  • History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine or intervention that includes one or more of the same components contained in the study vaccine.
  • Any history of myocarditis or pericarditis.
  • Coagulopathy or bleeding disorder considered a contraindication to IM injection or phlebotomy.
  • Dermatologic conditions that could affect local solicited AR assessments (for example, tattoos, psoriasis patches affecting skin over the deltoid areas).
  • Has received systemic immunosuppressive therapies (drugs or biologics) for >14 days in total within 6 months prior to Screening (for corticosteroids ≥10 mg/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, intra-articular, and topical steroids are allowed.
  • Has received or plans to receive any licensed/authorized vaccine (to include severe acute respiratory syndrome-related coronavirus-2 vaccine) ≤28 days prior to or within 28 days after each study intervention, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study intervention.
  • Has received systemic immunoglobulins or blood products within 3 months prior to the Screening Visit or plans for receipt during the study.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
  • Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to participate in an interventional clinical trial of an investigational vaccine or drug while participating in this study.
  • Phase 2 Part: Individuals who are participating/have participated in the Phase 1 part of the study are excluded.
  • Phase 1 Part: Any individual with laboratory abnormalities achieving thresholds defined in the protocol.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

1,285 participants in 15 patient groups, including a placebo group

Phase 1 Part: mRNA-1403 Dose Level 1
Experimental group
Description:
Participants will receive 2 intramuscular (IM) injections of mRNA-1403 at Dose Level 1.
Treatment:
Biological: mRNA-1403
Phase 1 Part: mRNA-1403 Dose Level 2
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1403 at Dose Level 2.
Treatment:
Biological: mRNA-1403
Phase 1 Part: mRNA-1403 Dose Level 3
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1403 at Dose Level 3.
Treatment:
Biological: mRNA-1403
Phase 1 Part: mRNA-1403 Dose Level 4 Regimen 1
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1403 at Dose Level 4.
Treatment:
Biological: mRNA-1403
Phase 1 Part: mRNA-1403 Dose Level 4 Regimen 2
Experimental group
Description:
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
Treatment:
Biological: Placebo
Biological: mRNA-1403
Phase 1 Part: mRNA-1405 Dose Level 1
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 1.
Treatment:
Biological: mRNA-1405
Phase 1 Part: mRNA-1405 Dose Level 2
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 2.
Treatment:
Biological: mRNA-1405
Phase 1 Part: mRNA-1405 Dose Level 3
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 3.
Treatment:
Biological: mRNA-1405
Phase 1 Part: mRNA-1405 Dose Level 4 Regimen 1
Experimental group
Description:
Participants will receive 2 IM injections of mRNA-1405 at Dose Level 4.
Treatment:
Biological: mRNA-1405
Phase 1 Part: mRNA-1405 Dose Level 4 Regimen 2
Experimental group
Description:
Participants will receive 1 IM injections of mRNA-1405 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
Treatment:
Biological: mRNA-1405
Biological: Placebo
Phase 1 Part: Placebo
Placebo Comparator group
Description:
Participants will receive 2 IM injections of study vaccine-matching placebo.
Treatment:
Biological: Placebo
Phase 2 Part: mRNA-1403 Dose Level 1
Experimental group
Description:
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 1.
Treatment:
Biological: mRNA-1403
Phase 2 Part: mRNA-1403 Dose Level 2
Experimental group
Description:
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 2.
Treatment:
Biological: mRNA-1403
Phase 2 Part: mRNA-1403 Dose Level 3
Experimental group
Description:
Participants will receive 1 IM injection of mRNA-1403 at Dose Level 3.
Treatment:
Biological: mRNA-1403
Phase 2 Part: Placebo
Placebo Comparator group
Description:
Participants will receive 1 IM injection of study vaccine-matching placebo.
Treatment:
Biological: Placebo

Trial contacts and locations

14

Loading...

Central trial contact

Moderna Clinical Trials Support Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems